{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:28:14Z","timestamp":1761326894547,"version":"build-2065373602"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Primary sclerosing cholangitis (PSC) is a cholestatic liver disease that frequently coexists with inflammatory bowel disease (IBD). The risk of infections in patients with concurrent PSC-IBD remains unclear. The aim of this study was to identify the event rate of infections and associated risk factors in PSC-IBD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched from inception to September 12, 2024 for studies examining event rate or risk factors for infection in patients with PSC-IBD. The primary outcome was the event rate of all-cause and site-specific infections as well as infection-related mortality. The secondary outcome was risk factors for infection. Random-effects models were used to calculate pooled odds ratios (OR) with 95% confidence intervals (CI) comparing the event rate of all-cause infections in PSC-IBD patients to those with just PSC and just IBD. I2 values more than 50% suggested substantial heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-one studies were included. The pooled event rate of all-cause infections in patients with PSC-IBD was 25.1% (95% CI, 17.0%-33.2%, I2\u2009=\u200999.2%). PSC-IBD patients had significantly increased odds of all-cause infection (OR 3.67, 95% CI, 2.07-6.52, I2\u2009=\u200941.9%), sepsis (OR 3.35, 95% CI, 2.29-4.91, I2\u2009=\u20099.1%), and infection-related mortality (OR 11.25, 95% CI, 2.03-62.37, I2\u2009=\u20090) compared to those with IBD but not those with PSC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with PSC-IBD appear to be at increased risk of all-cause infection, sepsis, and mortality compared to those with IBD alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jcag\/gwaf023","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:29:44Z","timestamp":1753183784000},"page":"163-178","source":"Crossref","is-referenced-by-count":0,"title":["Infections in primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9465-7534","authenticated-orcid":false,"given":"Navneet","family":"Natt","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Western University , London, Ontario N6A 5C1,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyrel","family":"Jones May","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Health Network, University of Toronto , Toronto, Ontario M5T 2S8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gurpreet","family":"Malhi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Western University , London, Ontario N6A 5C1,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Dumond","sequence":"additional","affiliation":[{"name":"Northern Ontario School of Medicine University , Thunder Bay, Ontario P7B 7A5,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliya","family":"Gulamhusein","sequence":"additional","affiliation":[{"name":"Toronto Centre Liver for Disease, University Health Network, University of Toronto , Toronto, Ontario M5T 2S8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parul","family":"Tandon","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University Health Network, University of Toronto , Toronto, Ontario M5T 2S8,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"2025102413220573200_gwaf023-B1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/ajg.2015.112","article-title":"ACG clinical guideline: primary sclerosing cholangitis","volume":"110","author":"Lindor","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2025102413220573200_gwaf023-B2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"key":"2025102413220573200_gwaf023-B3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ncpgasthep1004","article-title":"Infections and IBD","volume":"5","author":"Irving","year":"2008","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00042737-200601000-00012","article-title":"The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis","volume":"18","author":"Pohl","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4254\/wjh.v3.i4.83","article-title":"Infections in liver transplant recipients","volume":"3","author":"Romero","year":"2011","journal-title":"World J Hepatol"},{"key":"2025102413220573200_gwaf023-B6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1600-6143.2010.03384.x","article-title":"Infectious complications more than 1 year after liver transplantation: a 3-decade nationwide experience","volume":"11","author":"Aberg","year":"2011","journal-title":"Am J Transplant"},{"key":"2025102413220573200_gwaf023-B7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"2025102413220573200_gwaf023-B8","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2023","author":"Deeks","key":"2025102413220573200_gwaf023-B9"},{"key":"2025102413220573200_gwaf023-B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"year":"2021","author":"Wells","key":"2025102413220573200_gwaf023-B11"},{"key":"2025102413220573200_gwaf023-B12","doi-asserted-by":"crossref","first-page":"I4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025102413220573200_gwaf023-B13","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ibd\/izz325","article-title":"Activity of inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis predicts poorer clinical outcomes","volume":"26","author":"Peverelle","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/gut.34.2.242","article-title":"Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin","volume":"34","author":"Sandborn","year":"1993","journal-title":"Gut"},{"key":"2025102413220573200_gwaf023-B15","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/lt.25838","article-title":"Impact of preexisting inflammatory bowel disease on the outcome of liver transplantation for primary sclerosing cholangitis","volume":"26","author":"Irles-Depe","year":"2020","journal-title":"Liver Transpl"},{"key":"2025102413220573200_gwaf023-B16","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/ibd\/izaa317","article-title":"Association of anti-TNF therapy with increased risk of acute cholangitis in patients with primary sclerosing cholangitis","volume":"27","author":"Kulkarni","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.crohns.2012.06.001","article-title":"Impact of ileal pouch-anal anastomosis on the surgical outcome of orthotopic liver transplantation for primary sclerosing cholangitis","volume":"7","author":"Obusez","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2025102413220573200_gwaf023-B18","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s12879-014-0562-8","article-title":"Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis","volume":"14","author":"Rupp","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2025102413220573200_gwaf023-B19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.21960","article-title":"Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis","volume":"47","author":"Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"key":"2025102413220573200_gwaf023-B20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/gutjnl-2018-317791","article-title":"Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis","volume":"69","author":"Lemoinne","year":"2020","journal-title":"Gut"},{"key":"2025102413220573200_gwaf023-B21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000658-199010000-00017","article-title":"Surgical aspects of sclerosing cholangitis. Results in 178 patients","volume":"212","author":"Martin","year":"1990","journal-title":"Ann Surg"},{"key":"2025102413220573200_gwaf023-B22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/bjs.1800820836","article-title":"Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation","volume":"82","author":"Miki","year":"1995","journal-title":"Br J Surg"},{"key":"2025102413220573200_gwaf023-B23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2036.2012.05063.x","article-title":"The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis","volume":"35","author":"Navaneethan","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102413220573200_gwaf023-B24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.1840110103","article-title":"Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects","volume":"11","author":"Rabinovitz","year":"1990","journal-title":"Hepatology"},{"key":"2025102413220573200_gwaf023-B25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00042737-200306000-00013","article-title":"Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis","volume":"15","author":"Van de Vrie","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/lt.23868","article-title":"Recurrence of primary sclerosing cholangitis in pediatric liver transplant recipients","volume":"20","author":"Venkat","year":"2014","journal-title":"Liver Transpl"},{"key":"2025102413220573200_gwaf023-B27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MIB.0000000000000586","article-title":"Inflammatory bowel disease phenotype in pediatric primary sclerosing cholangitis","volume":"22","author":"Lascurain","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.surg.2005.07.014","article-title":"Surgical outcome in patients with primary sclerosing cholangitis undergoing ileal pouch-anal anastomosis: a case-control study","volume":"138","author":"Gorgun","year":"2005","journal-title":"Surgery"},{"key":"2025102413220573200_gwaf023-B29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.crohns.2013.10.008","article-title":"Colectomy for patients with ulcerative colitis and primary sclerosing cholangitis\u2014what next?","volume":"8","author":"Block","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2025102413220573200_gwaf023-B30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.crohns.2013.12.007","article-title":"Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis","volume":"8","author":"Pavlides","year":"2014","journal-title":"J Crohns Colitis"},{"key":"2025102413220573200_gwaf023-B31","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1016\/j.cgh.2021.02.006","article-title":"Primary sclerosing cholangitis-associated pouchitis: a distinct clinical phenotype","volume":"20","author":"Quinn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s11605-010-1223-x","article-title":"Primary sclerosing cholangitis and extraintestinal manifestations in patients with ulcerative colitis and ileal pouch-anal anastomosis","volume":"14","author":"Wasmuth","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"2025102413220573200_gwaf023-B33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.5217\/ir.2021.00042","article-title":"Association of young age and male sex with primary sclerosing cholangitis in Taiwanese patients with inflammatory bowel disease","volume":"20","author":"Weng","year":"2022","journal-title":"Intest Res"},{"key":"2025102413220573200_gwaf023-B34","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/ibd.21569","article-title":"Clinical characteristics of ulcerative colitis associated with primary sclerosing cholangitis in Korea","volume":"17","author":"Ye","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MPG.0000000000001078","article-title":"Clinical features and risk factors of autoimmune liver involvement in pediatric inflammatory bowel disease","volume":"63","author":"Bramuzzo","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025102413220573200_gwaf023-B36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jpeds.2021.07.047","article-title":"Sclerosing cholangitis in pediatric inflammatory bowel disease: early diagnosis and management affect clinical outcome","volume":"238","author":"Hensel","year":"2021","journal-title":"J Pediatr"},{"key":"2025102413220573200_gwaf023-B37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MPG.0000000000002855","article-title":"Vedolizumab therapy in children with primary sclerosing cholangitis: data from the pediatric primary sclerosing cholangitis consortium","volume":"71","author":"Laborda","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025102413220573200_gwaf023-B38","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MPG.0000000000001759","article-title":"Anti-TNF\u03b1 treatment in children and adolescents with combined inflammatory bowel disease and autoimmune liver disease","volume":"66","author":"Nedelkopoulou","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025102413220573200_gwaf023-B39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.transproceed.2020.09.011","article-title":"The course of ulcerative colitis after pediatric liver transplantation for sclerosing cholangitis","volume":"53","author":"Osiecki","year":"2021","journal-title":"Transplant Proc"},{"key":"2025102413220573200_gwaf023-B40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.dld.2018.02.014","article-title":"Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series","volume":"50","author":"Altwegg","year":"2018","journal-title":"Dig Liver Dis"},{"key":"2025102413220573200_gwaf023-B41","first-page":"949","article-title":"Safety of combination biologic and antirejection therapy post-liver transplantation in patients with inflammatory bowel disease","volume":"26","author":"Al Draiweesh","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2036.2012.05217.x","article-title":"Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients","volume":"36","author":"Mohabbat","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102413220573200_gwaf023-B43","first-page":"1015408","article-title":"Tumor necrosis factor alpha inhibition for inflammatory bowel disease after liver transplant for primary sclerosing cholangitis","volume":"2018","author":"Parekh","year":"2018","journal-title":"Case Rep Gastrointest Med"},{"key":"2025102413220573200_gwaf023-B44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ibd.21692","article-title":"Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis","volume":"18","author":"Hanouneh","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B45","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1053\/j.humpath.2003.07.015","article-title":"Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study","volume":"34","author":"Khettry","year":"2003","journal-title":"Hum Pathol"},{"key":"2025102413220573200_gwaf023-B46","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bjs.6210","article-title":"Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis","volume":"95","author":"Mathis","year":"2008","journal-title":"Br J Surg"},{"key":"2025102413220573200_gwaf023-B47","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/ibd\/izx096","article-title":"Natural history of established and De novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis","volume":"24","author":"Mouchli","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B48","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/DCR.0b013e318217eea7","article-title":"Short- and long-term surgical outcomes in patients undergoing proctocolectomy with ileal pouch-anal anastomosis in the setting of primary sclerosing cholangitis","volume":"54","author":"Mathis","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"2025102413220573200_gwaf023-B49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/DCR.0b013e3182315745","article-title":"Inflammatory bowel disease complicated by primary sclerosing cholangitis and cirrhosis: is restorative proctocolectomy safe?","volume":"55","author":"Lian","year":"2012","journal-title":"Dis Colon Rectum"},{"key":"2025102413220573200_gwaf023-B50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/00000658-199304000-00002","article-title":"Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis","volume":"217","author":"Kartheuser","year":"1993","journal-title":"Ann Surg"},{"key":"2025102413220573200_gwaf023-B51","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4292\/wjgpt.v4.i3.61","article-title":"Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy","volume":"4","author":"Treeprasertsuk","year":"2013","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2025102413220573200_gwaf023-B52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10350-008-9250-3","article-title":"Laparoscopic ileal pouch-anal anastomosis in patients with chronic ulcerative colitis and primary sclerosing cholangitis: a case-matched study","volume":"51","author":"Benavente-Chenhalls","year":"2008","journal-title":"Dis Colon Rectum"},{"key":"2025102413220573200_gwaf023-B53","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0016-5085(89)80078-2","article-title":"Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis","volume":"96","author":"Cangemi","year":"1989","journal-title":"Gastroenterology"},{"key":"2025102413220573200_gwaf023-B54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10350-004-6520-6","article-title":"Surgical management of ulcerative colitis in the presence of primary sclerosing cholangitis","volume":"46","author":"Poritz","year":"2003","journal-title":"Dis Colon Rectum"},{"key":"2025102413220573200_gwaf023-B55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025102413220573200_gwaf023-B56","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study","volume":"13","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025102413220573200_gwaf023-B57","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B58","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B59","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/ecco-jcc\/jjz094","article-title":"Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: a multicentre retrospective cohort study","volume":"13","author":"Guerra","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025102413220573200_gwaf023-B60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-2007-1018445","article-title":"Primary sclerosing cholangitis","volume":"17","author":"Jorge","year":"1985","journal-title":"Endoscopy"},{"key":"2025102413220573200_gwaf023-B61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF02047543","article-title":"Colectomy in patients with inflammatory bowel disease and primary sclerosing cholangitis","volume":"37","author":"Post","year":"1994","journal-title":"Dis Colon Rectum"},{"key":"2025102413220573200_gwaf023-B62","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3109\/00365529209011174","article-title":"Primary sclerosing cholangitis in patients with ulcerative colitis","volume":"27","author":"Rasmussen","year":"1992","journal-title":"Scand J Gastroenterol"},{"key":"2025102413220573200_gwaf023-B63","doi-asserted-by":"crossref","first-page":"e0135807","DOI":"10.1371\/journal.pone.0135807","article-title":"Solid organ transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity in a large single center cohort","volume":"10","author":"Schnitzler","year":"2015","journal-title":"PLoS One"},{"key":"2025102413220573200_gwaf023-B64","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12072-011-9260-4","article-title":"Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature","volume":"5","author":"Singal","year":"2011","journal-title":"Hepatol Int"},{"key":"2025102413220573200_gwaf023-B65","first-page":"229","article-title":"Primary sclerosing cholangitis associated with inflammatory bowel disease in cape town, 1975\u20141981","volume":"63","author":"Tobias","year":"1983","journal-title":"S Afr Med J"},{"key":"2025102413220573200_gwaf023-B66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0002-9610(66)90339-4","article-title":"Primary sclerosing cholangitis. A study of forty-two cases","volume":"111","author":"Warren","year":"1966","journal-title":"Am J Surg"},{"key":"2025102413220573200_gwaf023-B67","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.14309\/00000434-201610001-00629","article-title":"Ulcerative colitis with PSC have higher mortality, higher healthcare utilization, and worse clinical outcomes compared to UC only patients: national inpatient sample","volume":"111","author":"Bhardwaj","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2025102413220573200_gwaf023-B68","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/S0168-8278(14)61041-2","article-title":"P880 tertiary centre experience of the safety and efficacy of anti-TNFS for ulcerative colitis (UC) after liver transplantation","volume":"60","author":"Barnabas","year":"2014","journal-title":"J Hepatol"},{"key":"2025102413220573200_gwaf023-B69","doi-asserted-by":"crossref","first-page":"S-628","DOI":"10.1016\/S0016-5085(13)62324-0","article-title":"MO1291 ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis\u2014a single center experience","volume":"144","author":"Drastich","year":"2013","journal-title":"Gastroenterology"},{"key":"2025102413220573200_gwaf023-B70","doi-asserted-by":"crossref","first-page":"S401","DOI":"10.14309\/00000434-201710001-00728","article-title":"Inflammatory bowel disease outcomes and management following liver transplantation for primary sclerosing cholangitis: a single center study","volume":"112","author":"Fain","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"2025102413220573200_gwaf023-B71","first-page":"S198","article-title":"P472 infliximab therapy for inflammatory bowel disease in patients post liver transplatation","volume":"7","author":"Indriolo","year":"2013","journal-title":"J Crohns Colitis."},{"key":"2025102413220573200_gwaf023-B72","doi-asserted-by":"crossref","first-page":"S844","DOI":"10.14309\/00000434-201510001-01995","article-title":"The impact of biological therapy on liver transplant outcomes in pvvvatients with primary sclerosing cholangitis and inflammatory bowel disease","volume":"110","author":"Kochhar","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"2025102413220573200_gwaf023-B73","first-page":"702A","article-title":"Safety and efficacy of biologic therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a multicenter experience","volume":"70","author":"Mousa","year":"2019","journal-title":"J Hepatol"},{"key":"2025102413220573200_gwaf023-B74","first-page":"64","article-title":"Survival outcomes of primary sclerosing cholangitis patients with inflammatory bowel disease after liver transplantation","volume":"33","author":"Peverelle","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B75","doi-asserted-by":"crossref","first-page":"S356","DOI":"10.1093\/ecco-jcc\/jjx180.623","article-title":"P496 real-world outcomes of vedolizumab for inflammatory bowel disease post liver transplantation","volume":"12","author":"Peverelle","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2025102413220573200_gwaf023-B76","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study","volume":"21","author":"Schregel","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B77","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S1873-9946(12)60290-6","article-title":"P270 infliximab in patients with ulcerative colitis and primary sclerosing cholangitis before and after liver transplantation","volume":"6","author":"Indriolo","year":"2012","journal-title":"J Crohns Colitis."},{"key":"2025102413220573200_gwaf023-B78","doi-asserted-by":"crossref","first-page":"S636","DOI":"10.1016\/S0016-5085(19)38492-6","article-title":"Su1855 vedolizumab is not associated with increased infection risk","volume":"156","author":"Tse","year":"2019","journal-title":"Gastroenterology"},{"key":"2025102413220573200_gwaf023-B79","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/MEG.0000000000002510","article-title":"Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel disease","volume":"35","author":"Sayed","year":"2023","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025102413220573200_gwaf023-B80","first-page":"826","article-title":"P44 patients with ulcerative colitis and primary sclerosing cholangitis treated with a restorative proctocolectomy have a worse inflammatory and oncologic outcome","volume":"52","author":"Steinhagen","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"2025102413220573200_gwaf023-B81","first-page":"801A","article-title":"Inflammatory bowel disease-specific outcomes are not associated with initial bacterial cholangitis episode in patients with primary sclerosing cholangitis","volume":"70","author":"Rosenblatt","year":"2019","journal-title":"J Hepatol"},{"key":"2025102413220573200_gwaf023-B82","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.14309\/00000434-201610001-00684","article-title":"Colorectal surgery in inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) with concomitant primary sclerosing cholangitis (PSC) has worse hospital outcomes","volume":"111","author":"Ramsey","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"2025102413220573200_gwaf023-B83","doi-asserted-by":"crossref","first-page":"otae037","DOI":"10.1093\/crocol\/otae037","article-title":"Successful preoperative transjugular intrahepatic portosystemic shunt for portal decompression in patients with inflammatory bowel disease and cirrhosis requiring surgical intervention","volume":"6","author":"Karime","year":"2024","journal-title":"Crohns Colitis 360"},{"key":"2025102413220573200_gwaf023-B84","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1007\/s10620-023-08023-y","article-title":"Impact of inflammatory bowel disease subtypes on the post-liver transplant outcomes of patients with primary sclerosing cholangitis","volume":"68","author":"Lee","year":"2023","journal-title":"Dig Dis Sci"},{"key":"2025102413220573200_gwaf023-B85","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/ibd\/izad218","article-title":"Outcome of very early onset inflammatory bowel disease associated with primary sclerosing cholangitis: a multicenter study from the pediatric IBD Porto group of ESPGHAN","volume":"30","author":"Catassi","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B86","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/SLA.0000000000006041","article-title":"Ileal pouch-anal anastomosis in primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD)","volume":"278","author":"Maspero","year":"2023","journal-title":"Ann Surg"},{"key":"2025102413220573200_gwaf023-B87","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/ibd\/izad278","article-title":"Total proctocolectomy vs subtotal\/total colectomy for neoplasia in patients with inflammatory bowel disease and primary sclerosing cholangitis","volume":"30","author":"Dunleavy","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B88","doi-asserted-by":"crossref","first-page":"izae041","DOI":"10.1093\/ibd\/izae041","article-title":"The natural history of patients with pre-existing and de novo inflammatory bowel disease after solid organ transplantation: EITOS study of GETECCU","volume":"31","author":"Bast\u00f3n-Rey","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025102413220573200_gwaf023-B89","first-page":"S1512","article-title":"Demographic and clinical risk factors associated with acute cholangitis in patients with primary sclerosing cholangitis","volume":"76","author":"Medina-Morales","year":"2022","journal-title":"Hepatology."},{"key":"2025102413220573200_gwaf023-B90","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jcag\/gwad061.297","article-title":"A297 examining the impact of inflammatory bowel disease in primary sclerosing cholangitis patients post liver transplantation","volume":"7","author":"Malhi","year":"2024","journal-title":"J Can Assoc Gastroenterol"},{"key":"2025102413220573200_gwaf023-B91","doi-asserted-by":"crossref","first-page":"I1186","DOI":"10.1093\/ecco-jcc\/jjad212.0751","article-title":"P621 safety and effectiveness of vedolizumab and ustekinumab in inflammatory bowel disease patients after liver transplantation for primary sclerosing cholangitis: results from an ECCO-confer case series","volume":"18","author":"Holvoet","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025102413220573200_gwaf023-B92","doi-asserted-by":"crossref","first-page":"S-843","DOI":"10.1016\/S0016-5085(18)32861-0","article-title":"Safety and efficacy of biologic therapies for inflammatory bowel disease in patients with primary sclerosing cholangitis: an IBD remedy study","volume":"154","author":"Lawlor","year":"2018","journal-title":"Gastroenterology"},{"key":"2025102413220573200_gwaf023-B93","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jcag\/gwad061.285","article-title":"A285 comparison of adverse outcomes in patients with combined inflammatory bowel disease and primary sclerosing cholangitis versus isolated primary sclerosing cholangitis","volume":"7","author":"Dahiya","year":"2024","journal-title":"J Can Assoc Gastroenterol"},{"key":"2025102413220573200_gwaf023-B94","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.jhep.2020.11.029","article-title":"The multifactorial mechanisms of bacterial infection in decompensated cirrhosis","volume":"75","author":"Van der Merwe","year":"2021","journal-title":"J Hepatol"},{"key":"2025102413220573200_gwaf023-B95","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jhep.2023.02.030","article-title":"Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?","volume":"79","author":"Ricciuto","year":"2023","journal-title":"J Hepatol"},{"key":"2025102413220573200_gwaf023-B96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2008.07.010","article-title":"Use of glucocorticoids and risk of infections","volume":"8","author":"Cutolo","year":"2008","journal-title":"Autoimmun Rev"},{"key":"2025102413220573200_gwaf023-B97","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"key":"2025102413220573200_gwaf023-B98","doi-asserted-by":"crossref","first-page":"1098386","DOI":"10.3389\/fmicb.2023.1098386","article-title":"Role of gut microbiota in infectious and inflammatory diseases","volume":"14","author":"Maciel-Fiuza","year":"2023","journal-title":"Front Microbiol"},{"key":"2025102413220573200_gwaf023-B99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-2004-823069","article-title":"Technical aspects of ileoanal pouch surgery","volume":"17","author":"Carne","year":"2004","journal-title":"Clin Colon Rectal Surg"}],"container-title":["Journal of the Canadian Association of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/8\/5\/163\/64200349\/gwaf023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcag\/article-pdf\/8\/5\/163\/64200349\/gwaf023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:22:29Z","timestamp":1761326549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcag\/article\/8\/5\/163\/8246835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jcag\/gwaf023","relation":{},"ISSN":["2515-2084","2515-2092"],"issn-type":[{"type":"print","value":"2515-2084"},{"type":"electronic","value":"2515-2092"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,3]]}}}